Parkinson’s Disease (PD), Multiple System Atrophy research hub

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Dosing of Exidavnemab in Patients with Mild to Moderate Parkinson’s Disease on Stable Symptomatic Parkinson’s Disease Medication and in Patients with Multiple System Atrophy

This study tests a new medicine called exidavnemab for people with Parkinson's disease or multiple system atrophy. Researchers want to check if the medicine is safe, find out what side effects it might cause, and see how the human body handles different doses compared to a dummy drug.